ARRY-382-Keytruda Combo Shows Positive Results in Ovarian, Other Solid Cancers

ARRY-382-Keytruda Combo Shows Positive Results in Ovarian, Other Solid Cancers
The combination of Array BioPharma's immunotherapy ARRY-382 and Keytruda (pembrolizumab) has a manageable safety profile and has shown preliminary signs of effectiveness in pancreatic and ovarian cancer patients, a new Phase 1b study shows. The findings were recently presented at the Society for Immunotherapy of Cancer's (SITC) 32nd Annual Meeting in National Harbor, Maryland, in a poster titled, “Phase 1b/2 dose‐escalation study of ARRY‐382, an oral inhibitor of colony‐stimulating factor‐1 receptor (CSF1R), in combination with pembrolizumab for treatment of patients with advanced solid tumors.” ARRY-382 is an oral colony-stimulating factor 1 receptor (CSF1R) inhibitor. Because this receptor is needed for the immunosuppressive function of tumor-associated macrophages (TAMs), ARRY-382 is expected to enhance T-cell responses against tumor cells. Also, combining this drug with other immunotherapies that boost immune responses through different approaches may help improve patient outcomes. In preclinical studies, ARRY-382 had better responses when combined with a PD-1 inhibitor. The Phase 1b/2 trial (NCT02880371) was designed to test the safety, tolerability, and effectiveness of ARRY-382 in combination wit
Subscribe or to access all post and page content.